<DOC>
	<DOCNO>NCT01689727</DOCNO>
	<brief_summary>Many type cancer overexpress receptor vitamin folate ( Folate Receptor ) . This Phase 2 study utilize standard image radionuclide , technetium-99m , conjugated ligand ( EC20 ) design bind folate receptor . The study design open-label , baseline-controlled study .</brief_summary>
	<brief_title>Safety Efficacy FolateScan ( Technetium Tc 99m EC20 ) Subjects With Pituitary Tumors</brief_title>
	<detailed_description>This Phase 2 open-label , single-treatment group , baseline-controlled study design verify product safety , gather data percentage subject pituitary tumor increase uptake FolateScan tumor correlate immunohistochemical staining finding FolateScan image , subject pituitary tumor .</detailed_description>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Technetium Tc 99m-ethylenedicysteine</mesh_term>
	<criteria>Subjects must meet follow eligibility requirement enrol study : 1 . Subject must 18 year age old . 2 . Subject must pituitary tumor . 3 . Subject must good kidney function . 3 . Subject must provide write informed consent prior enrollment . Subjects must exclude follow condition present : 1 . Subject pregnant breastfeeding . 2 . Subject simultaneously participate another investigational drug study . 3 . Subject complete followup phase previous study loess 30 day prior enrollment study . 4 . Subject unable tolerate condition radionuclide image . 5 . Subject administer another radiopharmaceutical would interfere assessment Technetium Tc 99m EC20 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Pituitary Tumors</keyword>
</DOC>